全文获取类型
收费全文 | 75231篇 |
免费 | 6321篇 |
国内免费 | 3934篇 |
专业分类
耳鼻咽喉 | 2835篇 |
儿科学 | 257篇 |
妇产科学 | 2356篇 |
基础医学 | 4070篇 |
口腔科学 | 552篇 |
临床医学 | 8315篇 |
内科学 | 5147篇 |
皮肤病学 | 339篇 |
神经病学 | 650篇 |
特种医学 | 4672篇 |
外国民族医学 | 54篇 |
外科学 | 15767篇 |
综合类 | 13522篇 |
现状与发展 | 4篇 |
预防医学 | 1885篇 |
眼科学 | 233篇 |
药学 | 3200篇 |
14篇 | |
中国医学 | 173篇 |
肿瘤学 | 21441篇 |
出版年
2024年 | 76篇 |
2023年 | 735篇 |
2022年 | 1404篇 |
2021年 | 1910篇 |
2020年 | 1956篇 |
2019年 | 1704篇 |
2018年 | 1555篇 |
2017年 | 1972篇 |
2016年 | 2574篇 |
2015年 | 2257篇 |
2014年 | 4375篇 |
2013年 | 3763篇 |
2012年 | 4977篇 |
2011年 | 5445篇 |
2010年 | 4772篇 |
2009年 | 4588篇 |
2008年 | 4501篇 |
2007年 | 5049篇 |
2006年 | 4788篇 |
2005年 | 4615篇 |
2004年 | 3617篇 |
2003年 | 3203篇 |
2002年 | 2736篇 |
2001年 | 2630篇 |
2000年 | 2145篇 |
1999年 | 1611篇 |
1998年 | 1352篇 |
1997年 | 1166篇 |
1996年 | 704篇 |
1995年 | 646篇 |
1994年 | 542篇 |
1993年 | 316篇 |
1992年 | 280篇 |
1991年 | 238篇 |
1990年 | 212篇 |
1989年 | 185篇 |
1988年 | 183篇 |
1987年 | 152篇 |
1986年 | 134篇 |
1985年 | 108篇 |
1984年 | 61篇 |
1983年 | 39篇 |
1982年 | 53篇 |
1981年 | 44篇 |
1980年 | 32篇 |
1979年 | 24篇 |
1978年 | 23篇 |
1977年 | 14篇 |
1976年 | 10篇 |
1975年 | 6篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
51.
The aim of this study was to analyse if breast cancer survivors without other breast imaging surveillance attend population-based screening differently than women not previously diagnosed with breast cancer. Further, to analyse if any differences depended on the women’s age and years since previous cancer diagnosis.The study was a register-based retrospective cohort study of all women invited to participate in the national breast cancer screening programme in 2015–2016. Participation rates were calculated for breast cancer survivors without breast imaging within 21 months (2–4 years, 4–6 years, 6–10 years and more than 10 years after diagnosis) and for women without previous breast cancer. Relative differences in participation rates between the two groups were calculated.A total of 679,990 women were included in the study (2.6% breast cancer survivors).For breast cancer survivors, participation rates increased with increasing number of years since the previous cancer diagnosis peaking at 80.3% if the cancer diagnosis was more than 10 years ago. For women with no previous breast cancer, participation rate was 80.3%.The relative difference in participation was highest close to the breast cancer diagnosis and for the youngest women participation rates remained lower among breast cancer survivors even more than 10 years after the diagnosis.In conclusion, regardless of age and years since previous breast cancer diagnosis, breast cancer survivors had lower or similar participation rates than women with no previous cancer diagnosis. This indicated that as many as one fifth of the breast cancer survivors are at risk of inadequate surveillance. 相似文献
52.
胆囊癌是胆道系统最常见的恶性肿瘤,早期诊断困难,恶性程度高,易发生转移和复发。以手术为主的综合治疗是改善胆囊癌病人生存的唯一方法,但仍存在若干争议,如T2期是否需要行肝段切除、扩大根治术是否可以延长晚期胆囊癌病人的生存时间、各期胆囊癌淋巴结清扫范围等。结合术中所见、病理学检查等判断胆囊癌的肿瘤分期,并依据分期规范切除范围和淋巴结清扫是提高R0根治切除率的关键,且扩大根治术可以改善晚期病人的预后。 相似文献
53.
Diede L. Loopik Renée M. Ebisch Joanna IntHout Willem J. Melchers Leon F. Massuger Ruud L. Bekkers Albert G. Siebers 《International journal of cancer. Journal international du cancer》2020,147(3):897-900
Women with cervical intraepithelial neoplasia grade 3 (CIN3) have a long-lasting increased risk for noncervical high-risk human papillomavirus (hrHPV)-related (pre)malignancies. The aim of our study was to estimate this risk in women with recurrent CIN3 compared to women without a history of CIN3 and women with a single episode of CIN3. Women with a CIN3 diagnosis between 1990 and 2010 were obtained from the Dutch Pathology Registry (PALGA) and matched with a control group of women without CIN3. Analysis has been conducted in a subset of women with recurrent CIN3, defined as reoccurrence minimally 2 years post-treatment. Cases of noncervical hrHPV-related (pre)malignancies of the anus, vulva, vagina and oropharynx were identified until 2015 and incidence rate ratios (IRRs) were estimated. Then, 1,797 women with recurrent CIN3 were included with a median age of 34 years (range 18–76) and 31,594 person-years of follow-up. Women with recurrent CIN3 had an increased risk of developing noncervical hrHPV-related (pre)malignancies compared to women without CIN3 with an IRR of 25.96 (95%CI 6.32–106.58). The IRR was 2.48 (95% CI 1.87–3.30) compared to women with a single episode of CIN3. Studies on posttreatment follow-up and prophylactic hrHPV vaccination are warranted. 相似文献
54.
Kyung-Min Lee Eun Hye Hwang Seong Eun Kang Cheng Hyun Lee Hyebin Lee Hyeon Jeong Oh Kwangsoo Kim Jiwon Koh Han Suk Ryu 《JOURNAL OF BREAST CANCER》2020,23(6):599
PurposeA relatively low response to chemotherapy has been reported for hormone receptor (HR)-positive breast cancer. In this study, we investigated the role of tryptophanyl-transfer RNA synthetase (WARS) in the chemotherapeutic response of HR-positive breast cancer.MethodsPre-chemotherapeutic needle biopsy samples of 45 HR-positive breast cancer patients undergoing the same chemotherapeutic regimen were subjected to immunohistochemistry. To investigate the biological functions of WARS in HR-positive breast cancer, we conducted cell viability assay, flow cytometry analysis, caspase activity assay, Quantitative real-time polymerase chain reaction, and western blotting using WARS gene-modulated HR-positive breast cancer cells (T47D, ZR-75-1, and MCF7).ResultsWARS overexpression in HR-positive breast cancer patients showed a significant correlation with favorable chemotherapy response. Downregulation of WARS increased cell viability following docetaxel treatment in tumor cell lines. On the other hand, WARS overexpression sensitized the therapeutic response to docetaxel. Additionally, downregulation of WARS caused a decrease in the number of apoptotic cell populations by docetaxel. Poly (ADP-ribose) polymerase cleavage and caspase 3/7 activity were increased in docetaxel-treated tumor cells with WARS overexpression.ConclusionOur results suggest that WARS might be a potential predictor for chemotherapy response in patients with HR-positive breast cancer as well as a novel molecular target to improve chemosensitivity. 相似文献
55.
《Best Practice & Research: Clinical Haematology》2022,35(2):101374
Myeloproliferative neoplasms (MPNs) are clonal stem cell disorders commonly diagnosed in the seventh decade of life. With increasing access to blood surveillance, the number of adolescent and young adults (AYAs) diagnosed with MPNs is increasing. AYAs represent a unique cohort of MPN patients with differing challenges and psychosocial needs. The majority of AYA patients are females diagnosed with essential thrombocythaemia and most are asymptomatic at diagnosis. There is a striking predisposition to venous thrombotic events with a significant number experiencing splanchnic venous thrombosis (up to 70% of venous events). When compared to older patients, AYAs appear to have an indolent disease course. Interferon is the preferred cytoreductive agent in this population; indications for commencing treatment mirror those of older adults and are determined by the presence of high-risk features for thromboembolic events. 相似文献
56.
目的了解luminal型乳腺癌患者戈舍瑞林用药依从性情况,分析影响其依从性的相关因素。 方法根据纳入及排除标准,收集2015年1月至2017年12月重庆医科大学附属第一医院内分泌乳腺外科使用戈舍瑞林治疗的luminal型乳腺癌女性患者174例进行回顾性分析。中位随访时间16个月(范围:1~54个月),完成随访154例,失访20例,失访率为11.5%(20/174)。采用问卷调查评价其用药依从性,使用χ2检验和Mann-Whitney U检验比较不同特征患者依从性的差异;用Logistic回归分析影响患者依从性的相关因素。将患者分为≤40岁(103例)和>40岁(51例)2个亚组,进行亚组分析。 结果在完成随访的154例患者中,依从性好82例(53.2%,82/154),依从性差72例(46.8%,72/154)。≤40岁组患者中,55.3%(57/103)依从性好,而>40岁组患者中仅49.0%(25/51)依从性好。全部患者中,文化程度、医保类型、不良反应和是否了解疗程时间均与乳腺癌患者戈舍瑞林用药依从性有关(χ2=13.586、13.042、7.880、14.251,P均<0.050);Logistic回归分析结果显示:高中及以下学历、居民医保和不了解戈舍瑞林的疗程时间为影响依从性的危险因素(OR=2.772,95%CI:1.243~6.183,P=0.013;OR=5.188,95%CI:1.383~19.465,P=0.015; OR=3.363,95%CI:1.645~6.878,P=0.001)。亚组分析显示:文化程度、职业、医保类型和是否了解疗程时间是≤40岁患者戈舍瑞林用药依从性的影响因素(χ2=15.992、5.978、7.701、10.376,P均<0.050);不良反应及医保类型是>40岁患者用药依从性的影响因素(χ2=4.763、7.471,P均<0.050)。Logistic回归分析表明:高中及以下文化程度和不了解疗程时间是≤40岁患者用药依从性的危险因素(OR=5.126,95%CI:2.086~12.598,P<0.001; OR=3.631, 95%CI:1.500~8.792,P=0.004);居民医保是>40岁患者用药依从性的危险因素(OR=64.315,95%CI:2.513~1 646.042,P=0.012),不良反应是>40岁患者用药依从性的保护因素OR=0.189,95%CI=0.047~0.759,P=0.019)。 结论luminal型乳腺癌患者戈舍瑞林用药依从性较差,文化程度、医保类型及是否了解疗程时间都可能影响患者的依从性。≤40岁组和>40岁组患者依从性有差异,且影响因素不同,建议对不同年龄患者用药采用不同的干预措施。 相似文献
57.
《Taiwanese journal of obstetrics & gynecology》2020,59(4):541-545
ObjectiveTo investigate the safety and feasibility of our modified technique to perform lymph node excision up to the renal vein in cases of gynecological cancer.Materials and methods87 patients with endometrial or ovarian neoplasms underwent laparoscopic para-aortic lymphadenectomy (LPAL) up to the left renal vein were enrolled prospectively. During surgery, the surgeon was positioned to the right side of the patient and an additional trocar was introduced into the upper right abdomen. The laparoscopic video screen was placed to the side of the patient's head. Three-fan retractor forceps were used to hold up the duodenum and small bowel. The rest of the procedure was the same as conventional LPAL.ResultsThe median operating time for LPAL was 72 min (range: 40–115 min) and the median estimated blood loss was 45 ml (range: 15–1000 mL). There were two cases of intra-operative vascular injury. The median number of retrieved para-aortic lymph nodes (PALNs) was 18 (range: 10–37). Of the 87 patients, 11 patients had positive PALNs. None of the cases required laparotomy.ConclusionOur findings demonstrate that our modified LPAL technique is feasible, reproducible, can achieve good exposure and reduces surgical difficulty. 相似文献
58.
目的分析腹腔镜直肠癌前切除术中肠系膜下动脉不同结扎平面对患者预后的影响。
方法选取2007年6月至2014年6月间青岛市市立医院收治的行腹腔镜直肠癌前切除术136例患者为研究对象,根据肠系膜下动脉不同的结扎平面,分为保留左结肠动脉的低位结扎组(LL组)76例和不保留左结肠动脉的高位结扎组(HL组)60例。比较两组患者围手术期指标,随访并评价两组的预后。
结果两组手术时间、术中出血量、术后肛门排气时间、淋巴结清扫总数和第253组淋巴结清扫个数差异无统计学意义(t=6.109、4.339、8.386、0.233、0.198,P=0.318、0.416、0.512、0.821、0.669);LL组术后吻合口瘘的发生率明显低于HL组(χ2=5.186,P=0.029)。HL组术后3、5年总体生存率分别为80.00%和73.33%,LL组分别为77.63%和72.37%,两组比较差异无统计学意义(χ2=1.536、2.156,P=0.863、0.698)。
结论腹腔镜直肠癌前切除术中肠系膜下动脉不同结扎平面可获得相近的淋巴结清扫效果,保留左结肠动脉的低位结扎平面术后吻合口瘘的发生率更低,其他围手术期指标没有差异,联合第三站中央淋巴结清扫值得应用推广。 相似文献
59.
《Diagnostic and interventional imaging》2020,101(9):565-575
PurposeTo report the computed tomography (CT) features of pancreatic acinar cell carcinoma (ACC) and identify CT features that may help discriminate between pancreatic ACC and pancreatic ductal adenocarcinoma (PDA).Materials and methodsThe CT examinations of 20 patients (13 men, 7 women; mean age, 66.5 ± 10.7 [SD] years; range: 51–88 years) with 20 histopathologically proven pancreatic ACC were reviewed. CT images were analyzed qualitatively and quantitatively and compared to those obtained in 20 patients with PDA. Comparisons were performed using univariate analysis with a conditional logistic regression model.ResultsPancreatic ACC presented as an enhancing (20/20; 100%), oval (15/20; 75%), well-delineated (14/20; 70%) and purely solid (13/20; 65%) pancreatic mass with a mean diameter of 52.6 ± 28.0 (SD) mm (range: 24–120 mm) in association with visible lymph nodes (14/20; 70%). At univariate analysis, well-defined margins (Odds ratio [OR], 7.00; P = 0.005), nondilated bile ducts (OR, 9.00; P = 0.007), visible lymph nodes (OR, 4.33; P = 0.028) and adjacent organ involvement (OR, 5.67; P = 0.02) were the most discriminating CT features to differentiate pancreatic ACC from PDA. When present, lymph nodes were larger in patients with pancreatic ACC (14 ± 4.8 [SD]; range: 7–25 mm) than in those with PDA (8.8 ± 4.1 [SD]; range: 5–15 mm) (P = 0.039).ConclusionOn CT, pancreatic ACC presents as an enhancing, predominantly oval and purely solid pancreatic mass that most frequently present with no bile duct dilatation, no visible lymph nodes, no adjacent organ involvement and larger visible lymph nodes compared to PDA. 相似文献
60.
Glutathione S-transferase Polymorphisms in Head and Neck Squamous Cell Carcinoma Treated with Chemotherapy and/or Radiotherapy 下载免费PDF全文
Mauricio Pereira ManigliaAnelise RussoPatrícia Matos Biselli-ChicoteJuliana Garcia de Oliveira-CucoloGabriela Helena Rodrigues-Flemingjosé Victor -ManigliaÉrika Cristina PavarinoEny Maria Goloni-Bertollo 《Asian Pacific journal of cancer prevention》2020,21(6):1637-1644
Background/Aim: The Glutathione S-transferases (GSTs) are important carcinogen-metabolizing enzymes. Polymorphisms involved in these enzymes can modulate the development and treatment of head and neck cancer. To investigate the association of GSTs polymorphisms with head and neck cancer and risk factors, clinical-pathological features, and survival time of the patients treated with chemotherapy and/or radiotherapy. Methods: The GST gene polymorphisms were evaluated in 197 cases and 514 controls by PCR-RFLP-Polymerase Chain Reaction Restriction Fragment Length Polymorphism. Results: The GSTP-313 was associated with a decreased risk for HNSCC (p=0.050). The GSTP1 haplotype analysis revealed a higher frequency of the AC and AT haplotypes in the case group than in the control group (p=0.013 and p=0.019, respectively), and the opposite for G-C haplotype (p = 0.015). Yet, the different combinations between the genotypes were associated with an increased risk of cancer. The study showed no association between the polymorphisms and primary tumor site, clinical-pathological characteristics, treatment (chemotherapy and/or radiotherapy) and survival time of the patients. Conclusion: The GST polymorphisms combination showed an increased risk for carcinogenesis, and studies with larger casuistry can contribute to the clarification of the role in individual patient differences for the response to chemotherapy and/or radiotherapy and identify biomarkers of susceptibility. 相似文献